Free ABIM Internal Medicine Exam Prep

ACS with HEART score risk stratification, STEMI door-to-balloon ≤90 minutes, DAPT (ASA + P2Y12), HF with reduced EF GDMT (ARNI/BB/MRA/SGLT2 four-pillar therapy), atrial fibrillation with CHA2DS2-VASc and DOAC selection, ACC/AHA 2017 hypertension thresholds (≥130/80), PE with Wells/PERC and CTPA vs V/Q, aortic dissection, valvular disease.

GOLD 2024 COPD A/B/E classification and LAMA/LABA/ICS therapy, GINA 2024 asthma with ICS-formoterol SMART, obstructive sleep apnea, idiopathic pulmonary fibrosis (nintedanib, pirfenidone), sarcoidosis, pulmonary hypertension, ARDS, interstitial lung disease.

GERD, peptic ulcer disease, H. pylori ACG 2024 bismuth quadruple therapy first-line, IBD (UC and Crohn disease), celiac disease, cirrhosis with MELD-Na prioritization, HCC screening with ultrasound every 6 months, pangenotypic DAA regimens for HCV (glecaprevir-pibrentasvir, sofosbuvir-velpatasvir).

ADA 2024 Standards of Care: A1c <7% individualized, SGLT2/GLP-1 preferred for ASCVD/HF/CKD, tirzepatide and semaglutide for obesity; thyroid (Graves, Hashimoto, subacute thyroiditis), adrenal insufficiency and Cushing syndrome, pituitary disorders, osteoporosis with DEXA T-score ≤−2.5, bisphosphonates and denosumab rebound.

CAP IDSA/ATS 2019 inpatient vs outpatient, HIV antiretroviral therapy and opportunistic infection prophylaxis (PJP prophylaxis when CD4 <200), PrEP with tenofovir-emtricitabine and long-acting cabotegravir, endocarditis modified Duke criteria, sepsis Surviving Sepsis Campaign 2021 hour-1 bundle, TB latent/active, UTI and pyelonephritis.

Iron deficiency anemia with ferritin <30, B12/folate deficiency, MDS IPSS-R risk, acute leukemia (AML, APL with ATRA + arsenic trioxide), CML with TKIs, lymphoma (Hodgkin vs NHL), multiple myeloma CRAB criteria, VTE treatment duration, thrombophilia workup.

CKD KDIGO G1-G5 and albuminuria A1-A3, ACEi/ARB plus SGLT2 plus finerenone for diabetic CKD, AKI KDIGO staging, glomerulonephritis (nephritic vs nephrotic syndromes), electrolyte disorders (hyponatremia, hyperkalemia), acid-base, nephrolithiasis.

Osteoarthritis, rheumatoid arthritis early DMARD therapy (methotrexate, biologic DMARDs), SLE (ACR/EULAR 2019 criteria), vasculitis (giant cell arteritis, GPA/MPA ANCA), spondyloarthropathies, gout and urate-lowering therapy.

Ischemic stroke tPA (standard <3 hr, extended window up to 4.5 hr, mechanical thrombectomy 6-24 hr with imaging), migraine CGRP mAbs (erenumab, galcanezumab) and gepants, epilepsy first-line agents, multiple sclerosis, peripheral neuropathy, syncope.

Depression (PHQ-9 with SSRI first-line — sertraline, escitalopram), anxiety (GAD-7), bipolar disorder, alcohol use disorder (AUDIT, naltrexone/acamprosate), opioid use disorder MAT, somatic symptom disorders, serotonin syndrome, antipsychotic adverse effects.

Beers criteria 2023 potentially inappropriate medications, falls STEADI assessment, dementia evaluation with MMSE/MoCA, lecanemab (2023) and donanemab (2024) for early Alzheimer with ARIA monitoring, delirium CAM, polypharmacy, advance care planning.

Common inflammatory dermatoses (eczema, psoriasis, rosacea), drug eruptions including SJS/TEN, cutaneous manifestations of systemic disease, skin cancer recognition (melanoma ABCDE, BCC, SCC), cellulitis vs stasis dermatitis.

Contraception, preconception counseling, pregnancy in the medically complex patient, gestational hypertension and preeclampsia with severe features, postpartum issues, menopause and HRT individualized risk/benefit.

Acute red eye triage, open- vs closed-angle glaucoma, diabetic retinopathy, vertigo (BPPV Dix-Hallpike, Ménière, vestibular neuritis), epistaxis, acute otitis media and sinusitis.

USPSTF 2024 screening (breast cancer 40-74 biennial update, CRC 45-75, LDCT lung 50-80 with ≥20 pack-years, AAA 65-75 male smokers), ACIP 2024 adult immunizations (Shingrix ≥50, PCV20, RSV ≥60, COVID updated formulation), biostatistics, number needed to treat, test characteristics.

Perioperative medicine, preoperative cardiac risk (RCRI), chronic pain, opioid stewardship, anaphylaxis and food/drug allergy, angioedema (ACEi-induced vs hereditary C1-INH), immunodeficiencies.

Decision-making capacity assessment, informed consent, goals of care and surrogate decision-making, disclosure of medical errors, patient safety and quality improvement (Plan-Do-Study-Act), healthcare disparities, professionalism.